Evidence map›Paper›PMID 15175008›Full record

ArticleThe Biochemical journal2004

Overexpression of inactive arylsulphatase mutants and in vitro activation by light-dependent oxidation with vanadate.

Terri M Christianson, Chris M Starr, Todd C Zankel

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Terri M ChristiansonBioMarin Pharmaceutical Inc., 371 Bel Marin Keys Blvd., Novato, CA 94949, USA.
Chris M Starr
Todd C Zankel
BioMarin (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arylsulphatases B (ASB) and A (ASA) are subject to a unique post-translational modification that is required for their function. The modification reaction, conversion of an active-site cysteine into a formylglycine, becomes saturated when these enzymes are overexpressed. We have removed the possibility of in vivo modification by expressing mutants of ASB and ASA in which the active-site cysteine is substituted with a serine. These mutants are expressed much more efficiently when compared with the native enzymes under identical conditions. The purified ASB mutant can then be converted into catalytically active ASB in vitro using vanadate and light.

Indexed as

LightMutation, MissenseAnimalsArylsulfatasesCell LineCHO CellsCricetinaeDNA, ComplementaryEnzyme ActivationHumansLiverOxidation-ReductionTransfectionVanadatesArylsulfatasesDNA, ComplementaryVanadates

Identifiers

PMID15175008
PMCPMC1133815
OpenAlexW1984478075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.